{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T01:28:24Z","timestamp":1776994104437,"version":"3.51.4"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2020,4,9]]},"DOI":"10.1161\/jaha.120.016509","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T09:00:34Z","timestamp":1585731634000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":196,"title":["Coronavirus Disease 2019 (COVID\u201019): Do Angiotensin\u2010Converting Enzyme Inhibitors\/Angiotensin Receptor Blockers Have a Biphasic Effect?"],"prefix":"10.1161","volume":"9","author":[{"given":"Rami","family":"Sommerstein","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases Bern University Hospital Bern Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael M.","family":"Kochen","sequence":"additional","affiliation":[{"name":"Institute of Family Medicine University of Freiburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franz H.","family":"Messerli","sequence":"additional","affiliation":[{"name":"Department of Cardiology Bern University Hospital Bern Switzerland"},{"name":"Jagiellonian University Krakow Poland"},{"name":"Division of Cardiology Mount Sinai Health Medical Center Icahn School of Medicine New York NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Gr\u00e4ni","sequence":"additional","affiliation":[{"name":"Department of Cardiology Bern University Hospital Bern Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001017"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473\u20103099(20)30120\u20101"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.46234\/ccdcw2020.032"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.01.058"},{"key":"e_1_3_1_6_2","article-title":"The novel coronavirus 2019 (2019\u2010nCoV) uses the SARS\u2010coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells","author":"Hoffmann M","year":"2020","unstructured":"Hoffmann M, Kleine\u2010Weber H, Kr\u00fcger N, M\u00fcller M, Drosten C, P\u00f6hlmann S. The novel coronavirus 2019 (2019\u2010nCoV) uses the SARS\u2010coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv. 2020. 2020.01.31.929042. Posted January 31, 2020.","journal-title":"bioRxiv"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.510461"},{"key":"e_1_3_1_8_2","doi-asserted-by":"crossref","unstructured":"Sommerstein R Gr\u00e4ni C. Rapid response: re: preventing a covid\u201019 pandemic: ACE inhibitors as a potential risk factor for fatal Covid\u201019. BMJ 2020. Available at: http:\/\/www.bmj.com\/content\/368\/bmj.m810\/rr-2. Accessed March 20 2020.","DOI":"10.1136\/bmj.m810"},{"key":"e_1_3_1_9_2","unstructured":"HFSA\/ACC\/AHA statement addresses concerns re: using RAAS antagonists in COVID\u201019. March 17 2020. Available at: https:\/\/www.acc.org\/latest-in-cardi\u200bology\/\u200bartic\u200bles\/2020\/03\/17\/08\/59\/hfsa-acc-aha-state\u200bment-addre\u200bsses-conce\u200brns-re-using-raas-antag\u200bonists-in-covid-19. Accessed March 20 2020."},{"key":"e_1_3_1_10_2","unstructured":"European Societies of Cardiology . Position statement of the ESC Council on Hypertension on ACE\u2010inhibitors and angiotensin receptor blockers. March 13 2020. Available at: https:\/\/www.escar\u200bdio.org\/Counc\u200bils\/Counc\u200bil-on-Hyper\u200btensi\u200bon-(CHT)\/News\/posit\u200bion-state\u200bment-of-the-esc-counc\u200bil-on-hyper\u200btensi\u200bon-on-ace-inhib\u200bitors-and-ang. Accessed March 20 2020."},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30211-7"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.1585"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30566-3"},{"key":"e_1_3_1_14_2","article-title":"Estimation of risk factors for COVID\u201019 mortality\u2014preliminary results","author":"Caramelo F","year":"2020","unstructured":"Caramelo F, Ferreira N, Oliveiros B. Estimation of risk factors for COVID\u201019 mortality\u2014preliminary results. medRxiv. 2020. 2020.02.24.20027268. Posted: February 25, 2020.","journal-title":"medRxiv"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.14360"},{"key":"e_1_3_1_16_2","unstructured":"ECDC . Case definition and European surveillance for COVID\u201019 as of 2 March 2020. Available at: https:\/\/www.ecdc.europa.eu\/en\/case-defin\u200bition-and-europ\u200bean-surve\u200billan\u200bce-human-infec\u200btion-novel-coron\u200bavirus-2019-ncov. Accessed March 20 2020."},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.016219"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13293-017-0128-8"},{"key":"e_1_3_1_19_2","first-page":"1280","article-title":"Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling","volume":"19","author":"Walters TE","year":"2017","unstructured":"Walters TE, Kalman JM, Patel SK, Mearns M, Velkoska E, Burrell LM. Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling. Europace. 2017;19:1280\u20131287.","journal-title":"Europace"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5000321"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00110.2010"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00068.2005"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00726-014-1889-6"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087845"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/1470320316668435"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1267"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep19840"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.120.016509","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T11:24:31Z","timestamp":1715599471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.120.016509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,9]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,4,9]]}},"alternative-id":["10.1161\/JAHA.120.016509"],"URL":"https:\/\/doi.org\/10.1161\/jaha.120.016509","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,9]]},"assertion":[{"value":"2020-04-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e016509"}}